Nymox Pharmaceutical CORP (NYMXF) — 6-K Filings

6-K Filings (11)

• Nymox Pharma Wins Lawsuit Dismissal — Nov 7, 2025 Risk: low
  Nymox Pharmaceutical Corporation announced on November 7, 2025, that the U.S. District Court for the Central District of California granted its motion and that
• Nymox CEO Buys 102,844 Shares — Oct 22, 2025 Risk: medium
  Nymox Pharmaceutical Corporation reports that its CEO, Dr. Paul Averback, purchased 102,844 shares of the company's stock on October 20, 2025. This transaction
• Nymox Wins Legal Battles in US and Bahamas — Sep 23, 2025 Risk: medium
  Nymox Pharmaceutical Corporation announced on September 23, 2025, that the U.S. District Court for the Central District of California dismissed Randall Lanham's
• Nymox Faces Employee Complaints Amid Legal Battles — May 22, 2025 Risk: medium
  Nymox Pharmaceutical Corporation reported on May 22, 2025, that two former employees have filed complaints against the company. These individuals are reportedly
• Nymox Dismisses Delaware Lawsuit Against AscellaHealth — Mar 11, 2025 Risk: medium
  Nymox Pharmaceutical Corporation announced on March 11, 2025, that it dismissed a Delaware legal matter against AscellaHealth on March 7, 2025. This decision wa
• Nymox Pharma Files 6-K with Director Transaction Data — Jan 2, 2025 Risk: low
  Nymox Pharmaceutical Corp. filed a 6-K report on January 2, 2025, detailing financial information for the period ending September 30, 2024. The filing includes
• Nymox Pharmaceutical Stock Resumes Trading on OTCQB — Dec 17, 2024 Risk: medium
  Nymox Pharmaceutical Corporation announced on December 17, 2024, that its common stock has resumed trading on the OTCQB Venture Market under the symbol NYMXF. T
• Nymox Pharma Files 6-K Regarding 20-F Annual Report — Jul 18, 2024 Risk: low
  Nymox Pharmaceutical Corporation announced on July 18, 2024, that it has issued a press release concerning its annual report on Form 20-F. This announcement is
• Nymox MAA Expires with Danish Medicines Agency — Jul 16, 2024 Risk: medium
  Nymox Pharmaceutical Corporation announced on July 16, 2024, that its marketing authorization application (MAA) submission to the Danish Medicines Agency (DKMA)
• Nymox Pharma Dismisses Accounting Firm TPS THAYER — May 13, 2024 Risk: medium
  Nymox Pharmaceutical Corporation announced on April 4, 2024, the dismissal of TPS THAYER, LLC as its independent registered public accounting firm. The company'
• Nymox Pharma Resolves Bahamas Litigation — Mar 28, 2024 Risk: low
  Nymox Pharmaceutical Corporation announced on March 27, 2024, that it has secured a formal order from the Bahamas Supreme Court to resolve litigation initiated

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX